Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03620474Phase 1Completed

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Role: collaborator

NCT02195440Phase 1Completed

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Role: collaborator

NCT02828254Completed

A Follow-up Evaluation Study of PRI-724-1101

Role: collaborator

NCT01302405Phase 1Terminated

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

Role: lead

NCT02349009Phase 1Completed

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Role: lead

NCT01606579Phase 1Completed

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Role: lead

NCT01764477Phase 1Completed

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT02432027Phase 1Completed

Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test

Role: lead

NCT02413853Phase 2Withdrawn

Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer

Role: collaborator

All 9 trials loaded